<?xml version='1.0' encoding='UTF-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" 
         xmlns:bmdb="http://edrn.nci.nih.gov/rdf/rdfs/bmdb-1.0.0#"
         xmlns:edrn="http://edrn.nci.nih.gov/rdf/schema.rdf#"
         xmlns:edrntype="http://edrn.nci.nih.gov/rdf/types.rdf#" 
         xmlns:dc="http://purl.org/dc/terms/">
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:80</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/62"/>
    <bmdb:Description>Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene, hk11 (KLK11) is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Alternate splicing of this gene results in multiple transcript variants encoding distinct isoforms which are differentially expressed.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Prostate</bmdb:Organ>

    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Prostate and Urologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80#70"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80#105"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80#70">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/127"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80#105">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/287"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80/sensitivity-data-1"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:53</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/32"/>

    <bmdb:Description>Annexin 1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including Annexin 1.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Lung and Upper Aerodigestive</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Hanash Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53#31"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53#31">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/138"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/27"/>
        <bmdb:referencesResource rdf:resource="http://www.compass.fhcrc.org/caretweb/"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:41</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/20"/>
    <bmdb:Description>The best known marker for late stage and to a lesser degree early stage ovarian carcinomas - especially of serous and endometrioid histology. Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.
CA125, an epithelial sialomucin also called MUC16, is a heavily glycosylated protein with relatively high molecular weight and is the only approved marker for monitoring ovarian cancer. Although sialomucins are transmembrane in location, they can be found in serum. Most of the markers in this category have been identified through approaches in which human cancer cells are used as an antigenic stimulus in animals to raise antibodies, which can then efficiently detect the antigen in human serum. CA125 is the best documented and best performing single marker among the epithelial sialomucins. CA125 can be elevated in early pregnancy and with endometriosis, fibroids or infections of the genital tract. These conditions would affect specificity of the test and the possibility of false positive results. </bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41#21"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41#71"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/8"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41#21">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/119"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-4"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-5"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-6"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-7"/>

      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=0cef4927-50e7-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41#71">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-4"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/85"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=f8f637d2-50e6-11df-973d-17ec13bf30a1"/>

  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:40</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/19"/>
    <bmdb:Description>Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide, and its incidence in the United States is increasing. Despite advances in medical technology, the 5-year survival of patients with HCC improved minimally from 2% to 5% between 1981 and 1998. Since 90% of patients with HCC have underlying cirrhosis, patients with cirrhosis are candidates for HCC surveillance. The currently recommended surveillance tests for HCC are ultrasound evaluation of the liver (US), with or without measurement of serum alpha-fetoprotein (AFP). These tests are inadequately sensitive for use in screening, while ultrasound is also limited by the experience of the operator and on body habitus for adequate scanning. The performance of DCP to distinguish HCC from cirrhosis was compared to that of AFP or the lens culinaris agglutinin-reactive AFP (AFP-L3) and was shown to be superior, at a sensitivity of 92% and a specificity of 93%.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>

    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40#55"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40#43"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/33"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40#55">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/267"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40#43">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/111"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40/sensitivity-data-0"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40/sensitivity-data-1"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/23"/>
        <bmdb:referencesResource rdf:resource="http://www.med.umich.edu/gi/staff/Marrero.htm"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:42</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/21"/>
    <bmdb:Description>Amplification of a chromosome 19q region with the entire kallikrein family associated with ovarian cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42#72"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42#23"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/9"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42#72">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-2"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42#23">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/119"/>

    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-4"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-5"/>

      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:43</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/22"/>
    <bmdb:Description>Overexpression (protein) studies in ovarian cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>

    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43#24"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43#73"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>

    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/10"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43#24">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/119"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-1"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-4"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-5"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43#73">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>

    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-2"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>

  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:44</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/23"/>
    <bmdb:Description>Genomic analysis revealed upregulation in breast and ovarian epithelial tumors; protein overexpression studies confirmed finding.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>

    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44#25"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44#74"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/11"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44#25">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/119"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-2"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>

  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44#74">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-2"/>

      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:45</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/24"/>
    <bmdb:Description>Selected for study because of upregulation (mRNA) and overexpression (protein) studies in ovarian cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>

    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45#29"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45#75"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>

    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/12"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45#29">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/119"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-1"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-4"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-5"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45#75">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>

    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-2"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>

  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:46</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/25"/>
    <bmdb:Description>The literature offers some evidence that CA19-9 may be a marker for ovarian cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>

    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46#26"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46#76"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/13"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46#26">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/119"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-4"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-5"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46#76">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-2"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:47</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/26"/>
    <bmdb:Description>The literature offers some evidence that CA15-3 may be a marker for ovarian cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47#34"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47#77"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/15"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47#34">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/119"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-4"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-5"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>

  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47#77">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-2"/>

      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/48">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:48</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/27"/>
    <bmdb:Description>Osteopontin and other small integrin-binding ligand N-linked glycoproteins are emerging as important players in many stages of cancer progression.  Chosen for the EDRN by detection in microarray expression studies.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>

    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Pass New York University School of Medicine</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/48#47"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/48#48"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>

  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/48#47">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/24"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/48#48">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/136"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>

  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/28/49">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:49</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/28"/>
    <bmdb:Description>Differentially expressed mesothelial protein.  May comprise a biomarker panel with SPP1 (osteopontin).</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>

    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Pass New York University School of Medicine</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>

    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/28/49#50"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/28/49#49"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/68"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/28/49#50">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/136"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/28/49#49">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/24"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/29/50">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:50</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/29"/>
    <bmdb:Description>Matrix metallopeptidase 9 included for study due to microarray expression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Pass New York University School of Medicine</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/30/51">

    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:51</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/30"/>
    <bmdb:Description>Detected via microarray expression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Pass New York University School of Medicine</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>

  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/31/52">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:52</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/31"/>
    <bmdb:Description>Bladder cancer is the fourth most common malignancy of American men and the seventh most common malignancy of American women. Bladder cancer occurs in two clinically significant forms: (1) superficial (TNM: Ta, TIS, T1) and (2) invasive (TNM:&amp;gt;2). Seventy-five percent of individuals with bladder cancer have superficial disease, and only a minority (approximately 15%) are at risk for disease progression. Most individuals (approximately 70%) with superficial disease experience disease relapse over a 10-year period. The majority of recurrences occur within the first 2 years after the diagnosis. Therefore, these individuals require frequent surveillance for recurrence that includes cystoscopy and urine cytology every 3 months for 2 years and then anually, and radiographic evaluation of the upper urinary tract every year. the sensitivity and specificity of urinary cytology are 25-50% and 90-100%, respectively. The sensitivity and specificity of cystoscopy is 90-100% and 75%, respectively. Consequently, there is a need to improve the current practice of bladder cancer surveillance. Previous studies have shown the applicability of Microsatellite Analysis (MSA) to the diagnosis of bladder tumors. MSA can detect genetic changes indicative of carcinoma from urothelial cells obtained in voided urine specimens. The genetic profile of DNAA purified from urine is compared to that of DNA purified from peripheral lymphocytes that are considered &amp;quot;normal&amp;quot; for evidence of microsatellite instability (MSI) and loss of heterozygosity (LOH), which are genetic characteristics of epithelial tumors. MSA is considered positive if any of the 15 microsatellite markers included in a panel of 15 is positive. </bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>

    <bmdb:Organ>Bladder</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/31/52#30"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/24"/>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/31/52#30">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/108"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/24"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/34/54">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:54</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/34"/>

    <bmdb:Description>14-3-3 theta, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including 14-3-3 theta.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Lung and Upper Aerodigestive</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Hanash Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/34/54#32"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/34/54#32">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/138"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/34/54/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/27"/>
        <bmdb:referencesResource rdf:resource="http://www.compass.fhcrc.org/caretweb/"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/35/55">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:55</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/35"/>
    <bmdb:Description>LAMR1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including LAMR1.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Lung and Upper Aerodigestive</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Hanash Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/35/55#33"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/35/55#33">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/138"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/35/55/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/27"/>
        <bmdb:referencesResource rdf:resource="http://www.compass.fhcrc.org/caretweb/"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:56</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/36"/>
    <bmdb:Description>Since 90% of patients with hepatocellular carcinoma (HCC) have underlying cirrhosis, patients with cirrhosis are candidates for HCC surveillance.  Despite advances in medical technology, the 5-year survival of patients with HCC has improved minimally from 2% to 5% from 1981 to 1998.  This may be largely due to diagnosis at late stage disease.  These studies aim to compare the performance characteristics of the biomarkers AFP, DCP (des-gamma carboxyprothrombin) and AFP-L3 (lectin-bound AFP) in the early diagnosis of HCC.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56#44"/>
      </rdf:Bag>

    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56#44">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/111"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56/sensitivity-data-1"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56/sensitivity-data-2"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/37/57">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:57</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/37"/>
    <bmdb:Description>Since 90% of patients with hepatocellular carcinoma (HCC) have underlying cirrhosis, patients with cirrhosis are candidates for HCC surveillance. Despite advances in medical technology, the 5-year survival of patients with HCC has improved minimally from 2% to 5% from 1981 to 1998. This may be largely due to diagnosis at late stage disease. These studies aim to compare the performance characteristics of the biomarkers AFP, DCP (des-gamma carboxyprothrombin) and AFP-L3 (lectin-bound AFP) in the early diagnosis of HCC.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/37/57#45"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/37/57#45">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/111"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/43/64">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:64</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/43"/>
    <bmdb:Description>SCCA, a serine protease inhibitor physiologically present in the skin, has been detected in HCC tissue. SCCA is more strongly expressed in HCC than peritumoral tissue, and it also increases the AFP diagnostic capability up to 90%, but also increases the number of false positives. The biological role of SCCA in vivo and in particular in HCC tissue is still unknown since the embryonal derivation of the liver is quite different from that of the skin. SCCAIC, proposed as an alternative marker, is SCCA immunocomplexed with IgM.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/43/64#54"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/43/64#54">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/267"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:59</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/38"/>
    <bmdb:Description>PGP9.5 antigens were found to be targets of autoantibodies in newly diagnosed subjects with lung cancer. PGP9.5 is also highly expressed in non-small lung cancer cell line H157, having high invasive potential, and the expression of PGP9.5 in tumor cells enhances their invasive potential in vitro and in vivo.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Lung and Upper Aerodigestive</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Hanash Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59#46"/>

      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/75"/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59#46">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/138"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59/sensitivity-data-1"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/27"/>
        <bmdb:referencesResource rdf:resource="http://www.compass.fhcrc.org/caretweb/"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/39/60">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:60</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/39"/>
    <bmdb:Description>This study provides evidence for a predictive effect, in pre-diagnostic lung cancer sera, of a 3-biomarker panel for lung cancer. The panel is comprised of three antigens, annexin 1, LAMR1 and 14-3-3 theta.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Lung and Upper Aerodigestive</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Hanash Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/39/60#51"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/39/60#51">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/138"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/39/60/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/27"/>
        <bmdb:referencesResource rdf:resource="http://edrn.jpl.nasa.gov/ecas/dataset.php?typeID=urn:edrn:FHCRCHanashAnnexinLamr"/>
        <bmdb:referencesResource rdf:resource="http://www.compass.fhcrc.org/caretweb/"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/41/62">

    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:62</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/41"/>
    <bmdb:Description>Validation study was conducted to determine whether DJ-1 antigens are associated with autoantibodies in sera collected at the pre-symptomatic stage of lung cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Lung</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Lung and Upper Aerodigestive</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Hanash Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>

    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/41/62#52"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/41/62#52">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/138"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>

    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/41/62/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/41/62/sensitivity-data-1"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/27"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/42/63">

    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:63</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/42"/>
    <bmdb:Description>SCCA, a serine protease inhibitor physiologically present in the skin, has been detected in HCC tissue.  SCCA is more strongly expressed in HCC than peritumoral tissue, and it also increases the AFP diagnostic capability up to 90%, but also increases the number of false positives. The biological role of SCCA in vivo and in particular in HCC tissue is still unknown since the embryonal derivation of the liver is quite different from that of the skin.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/42/63#53"/>

      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/42/63#53">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/267"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/44/65">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:65</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/44"/>
    <bmdb:Description>Using the Liver Reference Set, the biomarker performance of SCCA, SCCA-IC, AFP-IC and DCP (PIVKA II) versus AFP in early stage LC and HCC patients, will be evaluated.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/44/65#56"/>
      </rdf:Bag>

    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/44/65#56">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/267"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/45/66">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:66</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/45"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/45/66#57"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/45/66#57">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/45/66/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/46/67">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:67</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/46"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/46/67#58"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/46/67#58">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/46/67/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/47/68">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:68</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/47"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/47/68#59"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/47/68#59">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/47/68/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/49/69">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:69</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/49"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/49/69#60"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/49/69#60">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/49/69/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/50/70">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:70</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/50"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/50/70#61"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/50/70#61">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/50/70/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/48/71">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:71</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/48"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/48/71#62"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/48/71#62">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/48/71/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/51/72">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:72</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/51"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/51/72#65"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/51/72#65">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/51/72/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/52/73">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:73</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/52"/>
    <bmdb:Description>Esphageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/52/73#63"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/52/73#63">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/52/73/sensitivity-data-0"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=dd5576ce-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:74</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/53"/>
    <bmdb:Description>Esophageal adenocarcinoma risk in Barrett&amp;apos;s esophagus is increased 30- to 125- fold versus the general population. Among all Barrett&amp;apos;s esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.
In 2005, Meltzer et al reported that hypermethylation of p16, RUNX3, and HPP1 occurs early in Barrett&amp;apos;s esophagus-associated neoplastic progression and predicts risk. Later, the group developed a tiered risk stratification model to predict progression in Barrett&amp;apos;s esophagus using epigenetic and clinical features, and also studied methylation levels and frequencies of individual genes using real-time quantitative methylation-specific PCR in 259 endoscopic esophageal biopsy specimens of different histologies. Among ten genes evaluated, five (NELL1, TAC1, SST, AKAP12, and CDH13) were methylated early and often in Barrett&amp;apos;s esophagus-associated progression.  In these studies, methylation status and levels correlated inversely with mRNA expression levels.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>

    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>

    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74#64"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74#64">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>

    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-3"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-4"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-5"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-6"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-7"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-8"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-9"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-10"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-11"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-12"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-13"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-14"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-15"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-16"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-17"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-18"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-19"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-20"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-21"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/81"/>

        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=d446e41b-50e6-11df-973d-17ec13bf30a1"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=da8c6bbd-50e6-11df-973d-17ec13bf30a1"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=b9c3b207-6a1d-11df-be96-f901d74aca33"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=ca45db18-50e6-11df-973d-17ec13bf30a1"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=bdc38f68-6a1d-11df-be96-f901d74aca33"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=c06c1a29-6a1d-11df-be96-f901d74aca33"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=c315683a-6a1d-11df-be96-f901d74aca33"/>
        <bmdb:referencesResource rdf:resource="https://edrn.jpl.nasa.gov/ecas/product.php?productID=ce009929-50e6-11df-973d-17ec13bf30a1"/>
  </bmdb:BiomarkerOrganStudyData>

  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:75</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/54"/>
    <bmdb:Description>Blood protein markers that provide more accurate or earlier diagnosis of prostate cancer should have a positive impact on prostate cancer treatment and management. Experimental evidence shows that thrombospondin-1 levels are elevated in patients with benign prostatic disease and repressed in patients with prostate cancer. Thrombospondin-1 levels do not correlate with prostate-specific antigen (PSA) levels and differentiate benign from malignant disease with 79% sensitivity and 81% specificity. The measurement of thrombospondin-1 could be used to assist the decision to obtain a biopsy in men with suspected prostate cancer, which could lead to a reduction in the number of unnecessary prostatic biopsies.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Prostate</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>

    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Prostate and Urologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Haab Van Andel Research Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75#66"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75#102"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
    <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/66"/>

  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75#66">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/127"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75#102">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/286"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>

      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-2"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-3"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/63/81">

    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:81</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/63"/>
    <bmdb:Description>The prostate cancer antigen 3 (PCA3/DD3) gene is a highly specific biomarker upregulated in prostate cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Prostate</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/64/82">

    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:82</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/64"/>
    <bmdb:Description>Mesothelin, a cell surface antigen, was isolated using an antibody that reacts with ovarian cancers and mesotheliomas. Although the function of mesothelin is unknown, it may play a role in cellular adhesion and is present on mesothelium, mesotheliomas, and ovarian cancers.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/64/82#81"/>

      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/64/82#81">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:77</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/56"/>
    <bmdb:Description>Human glandular kallikrein (hK2) has been shown to add important information regarding the early detection and staging of prostate cancer. Together with percent free PSA (%fPSA), hK2 may help to distinguish preoperatively between pT2 and pT3 prostate cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Prostate</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Prostate and Urologic</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77#68"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77#103"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77#68">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/127"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77#103">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/287"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77/sensitivity-data-1"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>

  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:78</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/57"/>
    <bmdb:Description>Kallikreins (KLKs) are highly conserved serine proteases that play key roles in a variety of physiological and pathological processes. KLK4 is regulated by androgens and is highly specific to prostate for expression. hK4 is intracellularly localized. KLK4 is predominantly expressed in the basal cells of the normal prostate gland and overexpressed in prostate cancer. hK4 has a unique structure and function compared with other members of the KLK family and may have a role in the biology and characterization of prostate cancer.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Prostate</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>

    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Prostate and Urologic</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>

    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78#69"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78#104"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78#69">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/127"/>

    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78#104">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/287"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78/sensitivity-data-0"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78/sensitivity-data-1"/>

      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/65/83">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:83</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/65"/>
    <bmdb:Description>Matrix metalloproteinases (MMPs) play key roles in tumorigenesis. A recent study has shown that epithelial expression of MMP-7 is higher in serous ovarian tumors than mucinous ovarian tumors, stromal expression of MMP-7 is higher in serous ovarian tumors, and that alterations in MMP-7 have been found in malignant serous ovarian tumors, while benign and borderline ovarian tumors share similar expression profiles.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>

    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/65/83#80"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/65/83#80">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/66/84">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:84</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/66"/>
    <bmdb:Description>Insulin-like growth factor binding protein 2 (IGFBP2), the second most abundant IGFBP in the circulation, is overexpressed in ovarian malignant tissues and in the serum and cystic fluid of ovarian cancer patients. IGFBP2 has been shown to enhance the invasion capacity of ovarian cancer cells. Treatment of NIH-OVCAR3 human epithelial ovarian cancer cells with IGFBP-2 stimulates cell growth significantly (p&amp;lt;.05) and potentiates the activation of (1) the extracellular signal regulated kinase (ERK1/2) signaling pathway, which transduces cell-specific growth and differentiation signals; (2) the stress-activated protein kinases/c-Jun N-terminal kinases (SAPK/JNK) pathway, which is activated by environmental stresses, inflammatory cytokines, growth factors and G-protein coupled receptor (GPCR) agonists; and (3) the p38 MAP kinase pathway, which mediates inflammatory and stress responses. Suppression of IGFBP-2, with its neutralizing antibody, significantly (p&amp;lt;.05) retards cell growth, blocks the activation of all three cascades of the MAPK pathways and downregulates the expression of a number of potential cancer-promoting cytokines.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/66/84#82"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/66/84#82">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/67/85">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:85</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/67"/>
    <bmdb:Description>Overexpression of SLPI has been measured in invasive and low malignant potential tumors compared with benign and normal tissues.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/67/85#83"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/67/85#83">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/68/86">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:86</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/68"/>
    <bmdb:Description></bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>

    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/68/86#84"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/68/86#84">

    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/69/87">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:87</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/69"/>
    <bmdb:Description>The inter-alpha-trypsin inhibitors (ITI) are a family of plasma protease inhibitors, assembled from a light chain - bikunin, encoded by AMBP - and five homologous heavy chains (encoded by ITIH1, ITIH2, ITIH3, ITIH4, and ITIH5), contributing to extracellular matrix stability by covalent linkage to hyaluronan. ITIH molecules have been shown to play a particularly important role in inflammation and carcinogenesis. A strong correlation (p &amp;lt; 0.001) has been found between ITIH2 expression and estrogen receptor (ER) expression indicating that ER may be involved in the regulation of this ECM molecule.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/69/87#85"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/69/87#85">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/70/88">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:88</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/70"/>
    <bmdb:Description>CTAP-III was identified to be significantly higher in venous than in arterial blood. CTAP III levels decreased after lung tumor resection (P = .01). In two independent population cohorts, CTAP III was significantly associated with lung cancer. CTAP-III may also modify breast cancer cells and surrounding extracellular matrix to facilitate metastasis.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/70/88#86"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/70/88#86">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/71/89">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:89</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/71"/>
    <bmdb:Description>Spondin-2 has been identified as potential ovarian cancer biomarkers. In a 2007 study (Simon, I. Gynecol Oncol. 2007 Jul;106(1):112-8. Epub 2007 May 8) Spondin 2, B7-H4, and DcR3 were evaluated for their ability to identify clinical disease. The three novel markers and CA125 were elevated in serum of ovarian cancer patients as compared to normal controls.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/71/89#87"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/71/89#87">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/72/90">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:90</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/72"/>
    <bmdb:Description>In laboratory testing, TT, in a panel (including apolipoprotein A-1, transferrin, and CA125) has been shown to be a highly sensitive (96%) predictor of early stage ovarian cancer and endometrial cancer.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/72/90#88"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/72/90#88">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/73/91">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:91</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/73"/>
    <bmdb:Description>In laboratory testing, transferrin, in a panel (including apolipoprotein A-1, transthyretin, and CA125) has been shown to be a highly sensitive (96%) predictor of early stage ovarian cancer and endometrial cancer.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/73/91#89"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/73/91#89">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/74/92">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:92</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/74"/>
    <bmdb:Description>B2M has been shown to be the target molecule of an antibody pool against SKOV3 ovarian cancer cells. Studies have also indicated that specific antibody of B2M can inhibit the growth of SKOV3. In addition, overexpression of B2M promotes the growth of SKOV3 cells in vitro.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/74/92#90"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/74/92#90">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/75/93">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:93</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/75"/>
    <bmdb:Description>APO-1/Fas receptor (FasR) is a cell surface receptor that, when activated, triggers apoptosis. It has been postulated that this receptor may be involved in the clearance of benign ovarian epithelial inclusion cysts (IC). An observed decreased expression of FasR in malignant ovarian epithelial neoplasms as compared with benign ovarian epithelial lesions suggests that a decreased sensitivity to Fas-mediated apoptosis may be involved in ovarian epithelial carcinogenesis.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/75/93#91"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/75/93#91">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/76/94">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:94</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/76"/>
    <bmdb:Description>CCL11 signaling plays an important role in proliferation and invasion of ovarian carcinoma cells. Circulating levels of CCL11 in sera of patients with ovarian cancer were significantly lower than those in healthy women or women with breast, lung, liver, pancreatic, or colon cancer. Cultured ovarian carcinoma cells absorbed soluble CCL11, indicating that absorption by tumor cells could be responsible for the observed reduction of serum level of CCL11 in ovarian cancer. Postoperative CCL11 levels in women with ovarian cancer negatively correlated with relapse-free survival. Ovarian tumors overexpressed three known cognate receptors of CCL11, CC chemokine receptors (CCR) 2, 3, and 5. Strong positive correlation was observed between expression of individual receptors and tumor grade. CCL11 potently stimulated proliferation and migration/invasion of ovarian carcinoma cell lines. The growth-stimulatory effects of CCL11 were likely associated with activation of extracellular signal-regulated kinase 1/2, MEK1, and STAT3 phosphoproteins and with increased production of multiple cytokines, growth factors, and angiogenic factors. Inhibition of CCL11 signaling by the combination of neutralizing antibodies against the ligand and its receptors significantly increased sensitivity to cisplatin in ovarian carcinoma cells.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/76/94#92"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/76/94#92">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/77/95">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:95</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/77"/>
    <bmdb:Description>MMP3 has been shown to be overexpressed in cisplatin-resistant and sensitive ovarian carcinoma cells.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/77/95#93"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/77/95#93">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/78/96">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:96</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/78"/>
    <bmdb:Description>P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer. Elevated EGFR is associated with less favorable disease outcome in ovarian cancer, related in part to EGFR activation of signaling cascades that lead to enhanced matrix metalloproteinase expression and/or function.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/78/96#94"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/78/96#94">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/79/97">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:97</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/79"/>
    <bmdb:Description>Elevated levels of serum PRL in ovarian and endometrial cancers have been reported, indicating a potential role for PRL in endometrial and ovarian carcinogenesis. Serum PRL levels are significantly elevated in women with a strong family history of ovarian cancer. There is evidence for dramatically increased expression of PRL receptor in ovarian and endometrial tumors as well as in endometrial hyperplasia, signifying the importance of PRL signaling in malignant and premalignant conditions. PRL mRNA has been shown to be expressed in ovarian and endometrial tumors, indicating the presence of an autocrine loop. PRL potently induces proliferation in several ovarian and endometrial cancer cell lines. Binding of PRL to its receptor is followed by rapid phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, mitogen-activated protein kinase/ERK kinase 1, signal transducer and activator of transcription 3, CREB, ATF-2, and p53 and activation of 37 transcription factors in ovarian and endometrial carcinoma cells. PRL also activates Ras oncogene in these cells.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/79/97#95"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/79/97#95">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/80/98">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:98</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/80"/>
    <bmdb:Description>Leptin, a secreted protein of the ob gene by white adipose tissue, plays an important role in the regulation of food intake and energy consumption in the brain and acts as a potential growth stimulator in normal and neoplastic breast cancer cells. The expression of leptin receptors in immortalized ovarian surface epithelium (IOSE) and ovarian cancer cell lines, and potential effect of leptin on the cell growth and activation of mitogen-activated protein kinases (MAPKs) in the BG-1 ovarian cancer cell line has been tested. Both short and long isoforms of leptin receptors are expressed in IOSE-80PC (a post-crisis line), BG-1, OVCAR-3, and SKOV-3 cells. In addition, treatment with leptin resulted in the growth stimulation of BG-1 cells, an activation of ERK1/2 and inhibition of constitutive phosphorylation of p38 MAPK.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/80/98#96"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/80/98#96">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/81/99">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:99</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/81"/>
    <bmdb:Description>MIF RNAi significantly inhibited MIF expression in HO-8910 and OVCAR-3 cells and decreased cell proliferation of the two cells (P&amp;lt;0.05). Positive expression of MIF protein was detected in 53.5% of ovarian carcinoma tissues and was positively correlated to clinical stages of patients (P&amp;lt;0.01).</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/81/99#97"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/81/99#97">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/100">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:100</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/27"/>
    <bmdb:Description>Osteopontin (OPN) is a secreted, integrin-binding matrix phosphorylated glycoprotein that is overexpressed in many advanced cancers. The expression of OPN by HO-8910 ovarian cancer cells greatly promoted the progression of ovarian cancer. OPN expression dramatically increased the colony formation of ovarian cancer cells in vitro and tumor growth in vivo. Under the stress induced by serum depletion or curcumin treatment, OPN expression promoted the survival of ovarian cells through preventing stress-induced apoptosis. At the molecular level, both endogenous and exogenous OPN expression activated the PI3-K/Akt survival pathway and dramatically decreased p53 expression under serum depletion. In addition, HIF-1alpha was induced in OPN-producing cells under normoxia. Furthermore, we also found that inhibition of the PI3-K/Akt pathway attenuated OPN-mediated HIF-1alpha up-regulation in ovarian cancer cells. Taken together, these results indicate that OPN can increase the survival of ovarian cancer cells under stress conditions in vitro and promote the late progression of ovarian cancer in vivo, and the survival-promoting functions of OPN are mediated through Akt activation and the induction of HIF-1alpha expression.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/100#98"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/27/100#98">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/82/101">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:101</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/82"/>
    <bmdb:Description>Overexpression of the imprinted insulin-like growth factor-II (IGF2) is a prominent characteristic of gynecologic malignancies. Elevated IGF2 expression is a frequent event in serous ovarian cancer and this occurs in the absence of IGF2 loss of imprinting (LOI).</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/82/101#99"/>
      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>

  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/82/101#99">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/83/102">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:102</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/83"/>
    <bmdb:Description></bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Colon</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Brenner University of Michigan</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/84/103">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:103</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/84"/>
    <bmdb:Description></bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/85/104">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:104</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/85"/>
    <bmdb:Description></bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/86/105">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:105</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/86"/>
    <bmdb:Description>Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC).</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Liver</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/87/106">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:106</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/87"/>
    <bmdb:Description>Somatic KRAS mutation is an early well-known event in colorectal carcinogenesis.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Colon</bmdb:Organ>
    <bmdb:Phase>One</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Brenner University of Michigan</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas/>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/88/107">

    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:107</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/88"/>
    <bmdb:Description></bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/88/107#100"/>

      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/88/107#100">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:108</bmdb:URN>

    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/89"/>
    <bmdb:Description>The PLCO accepted the phase II reports (SPORE/EDRN/PLCO Ovarian Validation Study) and sent identical sets to the assay sites.  Each set included sera for cases most proximate to the diagnosis of ovarian cancer which (on average) was about 9 months prior. There were 951 controls matched by age and timing of specimen collection including 475 general population controls, 238 with false positive CA 125, and 238 with family history of breast or ovarian cancer.   90 quality control specimens were also included. Investigators tested their markers and marker panels blinded to the status of the cases.  PLCO unblinded the data in stages to allow further algorithm development.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Ovary</bmdb:Organ>
    <bmdb:Phase>Three</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>Breast and Gynecologic</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108#101"/>

      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108#101">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/312"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108/sensitivity-data-0"/>

        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108/sensitivity-data-1"/>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108/sensitivity-data-2"/>
      </rdf:Bag>
    </bmdb:SensitivityDatas>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/90/109">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:109</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/90"/>

    <bmdb:Description>Experimental findings suggest that hypermethylation of p16, RUNX3 and HPP1 in Barrett&amp;apos;s Esophagus or low-grade dysplasia may have implications regarding risk stratification, early esophageal adenocarcinoma detection, and the appropriate endoscopic surveillance interval for patients with Barrett&amp;apos;s Esophagus.</bmdb:Description>
    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/90/109#106"/>

      </rdf:Bag>
    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/90/109#106">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
    <bmdb:SensitivityDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/90/109/sensitivity-data-0"/>

      </rdf:Bag>
    </bmdb:SensitivityDatas>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/54"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:BiomarkerOrganData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/91/110">
    <bmdb:URN>urn:edrn:bmdb:biomarkerorgan:110</bmdb:URN>
    <bmdb:Biomarker rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/91"/>
    <bmdb:Description>In these experiments, the endpoint of progression was defined as high-grade dysplasia, and Barrett&amp;apos;s esophagus progressor patients were defined as Barrett&amp;apos;s esophagus patients with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. Barrett&amp;apos;s esophagus specimens were stratified into high-risk, intermediate-risk or low-risk groups. This three-tiered stratification method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model.  Progression-free survivals differed significantly among the three risk groups. Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction accuracy.</bmdb:Description>

    <bmdb:PerformanceComment></bmdb:PerformanceComment>
    <bmdb:Organ>Esophagus</bmdb:Organ>
    <bmdb:Phase>Two</bmdb:Phase>
    <bmdb:QAState>Under Review</bmdb:QAState>
    <bmdb:AccessGrantedTo>GI and Other Associated</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Curators</bmdb:AccessGrantedTo>

    <bmdb:AccessGrantedTo>National Cancer Institute</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Feng Fred Hutchinson Cancer Research Center</bmdb:AccessGrantedTo>
    <bmdb:AccessGrantedTo>Crichton JPL</bmdb:AccessGrantedTo>
    <bmdb:hasBiomarkerOrganStudyDatas>
      <rdf:Bag>
        <rdf:li rdf:resource="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/91/110#107"/>
      </rdf:Bag>

    </bmdb:hasBiomarkerOrganStudyDatas>
  </bmdb:BiomarkerOrganData>
  <bmdb:BiomarkerOrganStudyData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/91/110#107">
    <bmdb:referencesStudy rdf:resource="http://edrn.nci.nih.gov/data/protocols/137"/>
    <bmdb:DecisionRule></bmdb:DecisionRule>
        <bmdb:referencedInPublication rdf:resource="http://edrn.jpl.nasa.gov/bmdb/publications/view/51"/>
  </bmdb:BiomarkerOrganStudyData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80/sensitivity-data-0">
    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing cases with Gleason grade &amp;gt;=7 (n=30) to the pool of controls and cases with Gleason grade &amp;lt;7 (n=93), the AUC was 0.59 (0.46, 0.71). No specific cutoff was preselected for this analysis.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/62/80/sensitivity-data-1">

    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.51 (0.41, 0.62). No specific cutoff was preselected for this analysis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/32/53/sensitivity-data-0">
    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis.  Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>51</bmdb:Sensitivity>
    <bmdb:Specificity>82</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-0">
    <bmdb:SensSpecDetail>Cases chosen with diagnosis of ovarian cancer (on average) 9 months prior. Controls were matched to cases by age and timing of specimen collection including general population controls (50%), false positive CA125 (25%), and family history of breast cancer (25%).  All cases (n=60).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>41</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-1">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;lt;= 6 months after draw (n=25)</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>79</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-2">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;gt; 6 months after draw (n=35)</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>15</bmdb:Sensitivity>

    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-3">
    <bmdb:SensSpecDetail>DEFINITIONS: The SENSITIVITY of a decision rule (that translates what is measured in the physical quantity into a call of cancer or not cancer in the individual) is the probability that the rule is correct when the individual screened has cancer. The SPECIFICITY of a rule is the probability that the rule is correct when the individual being screened does not have cancer. The POSITIVE PREDICTIVE VALUE (PPV) of a rule is the probability that the individual has cancer given that the rule makes the call of cancer. NEGATIVE PREDICTIVE VALUE (NPV) of a rule is the probability that the individual does not have cancer when the rules makes a call of no cancer. PREVALENCE is the number of all cases of a condition in a population during a particular period, generally expressed as a ratio in which the number of events is the numerator and the population at risk is the denominator.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-4">

    <bmdb:SensSpecDetail>The dataset contains the original values and the log transformed values for CA125, CA15.3, CA19.9, CA72.4, KLK6 (aka HK6), HE4, and OV110 (aka B7-H4). Created by Allison Vitonis. Partners used plate-based assay for B7-H4(Diadexus), HE4, and Kallikrein 6 (as described in (Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, and Katsaros D, Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol, 2003. 21(6): p. 1035-43)). Platform-based assays (Roche) were used for CA125, CA15.3, CA72.4 and CA19.9. Unless the volume was insufficient assays were run in duplicate and averaged. These seven markers were chosen based on their performance in the phase II (pre-PLCO) data. This file is available in Related Resources section, &amp;quot;Harvard_markers_11132008.xls&amp;quot; [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-5">
    <bmdb:SensSpecDetail>For late stage (within 12 months of diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-6">
    <bmdb:SensSpecDetail>DEFINITIONS: The SENSITIVITY of a decision rule (that translates what is measured in the physical quantity into a call of cancer or not cancer in the individual) is the probability that the rule is correct when the individual screened has cancer. The SPECIFICITY of a rule is the probability that the rule is correct when the individual being screened does not have cancer. The POSITIVE PREDICTIVE VALUE (PPV) of a rule is the probability that the individual has cancer given that the rule makes the call of cancer. NEGATIVE PREDICTIVE VALUE (NPV) of a rule is the probability that the individual does not have cancer when the rules makes a call of no cancer. PREVALENCE is the number of all cases of a condition in a population during a particular period, generally expressed as a ratio in which the number of events is the numerator and the population at risk is the denominator.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/20/41/sensitivity-data-7">
    <bmdb:SensSpecDetail>Pre-PLCO dataset, all records unblinded as of 3-13-2008. This spreadsheet contains the following four tabs: Biomarker Data, Demographic Data, Ppt Cancer Hx, Family Cancer Hx.  The marker values have been standardized (Each marker was first log transformed to yield a normal distribution in the controls and then each was centered and scaled so that the controls had a mean of 0 and a standard deviation of 1). This dataset was distributed to the group by Mark Thornquist.  This file is available in Related Resources section, &amp;quot;Final_data_set_unblinded_3-13-2008_a.xls&amp;quot; [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40/sensitivity-data-0">
    <bmdb:SensSpecDetail>Evaluation of DCP with AFP (biomarker combination) in early stage hepatocellular carcinoma. Early stage determined by tumor size via imaging. 419 cases total in the study; 208 early stage cases used in this analysis. Controls are individuals with chronic cirrohsis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>70</bmdb:Sensitivity>

    <bmdb:Specificity>80</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/19/40/sensitivity-data-1">
    <bmdb:SensSpecDetail>Evaluation of DCP with AFP (biomarker combination) in cases with viral hepatitis (subset of cases inclusive of early and more advanced stage). Controls are individuals with chronic cirrohsis.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>78</bmdb:Sensitivity>
    <bmdb:Specificity>84</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-0">

    <bmdb:SensSpecDetail>For all cases, using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>22</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>

  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-1">
    <bmdb:SensSpecDetail>For early stage (more than 12 months prior to diagnosis), using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>28</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-2">
    <bmdb:SensSpecDetail>For late stage (within 12 months of diagnosis), using general population controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>14</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-3">
    <bmdb:SensSpecDetail>For all cases, using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>24</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-4">
    <bmdb:SensSpecDetail>For early stage (more than 12 months prior to diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>28</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/21/42/sensitivity-data-5">
    <bmdb:SensSpecDetail>For late stage (within 12 months of diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>18</bmdb:Sensitivity>

    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-0">
    <bmdb:SensSpecDetail>Cases with diagnosis of ovarian cancer (on average) 9 months prior to collection. Controls were matched to cases by age and timing of specimen collection including general population controls (50%), false positive CA125 (25%), and family history of breast cancer (25%). All cases (n=60).</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>32</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-1">

    <bmdb:SensSpecDetail>Cases diagnosed &amp;lt;= 6 months after draw (n=25).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>48</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-2">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;gt; 6 months after draw (n=35).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>21</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-3">
    <bmdb:SensSpecDetail>For all cases, using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>25</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-4">
    <bmdb:SensSpecDetail>For early stage (more than 12 months prior to diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>34</bmdb:Sensitivity>

    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/22/43/sensitivity-data-5">
    <bmdb:SensSpecDetail>For late stage (within 12 months of diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>9</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-0">

    <bmdb:SensSpecDetail>Cases chosen with diagnosis of ovarian cancer (on average) 9 months prior. Controls were matched to cases by age and timing of specimen collection including general population controls (50%), false positive CA125 (25%), and family history of breast cancer (25%). All cases (n=60).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>25</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>

  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-1">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;lt;= 6 months after draw (n=25).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>48</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/23/44/sensitivity-data-2">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;gt; 6 months after draw (n=35).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>6</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-0">
    <bmdb:SensSpecDetail>Cases chosen with diagnosis of ovarian cancer (on average) 9 months prior. Controls were matched to cases by age and timing of specimen collection including general population controls (50%), false positive CA125 (25%), and family history of breast cancer (25%). All cases (n=60).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>42</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-1">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;lt;= 6 months after draw (n=25).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>68</bmdb:Sensitivity>

    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-2">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;gt; 6 months after draw (n=35).</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>23</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-3">

    <bmdb:SensSpecDetail>For all cases, using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>38</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>

  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-4">
    <bmdb:SensSpecDetail>For early stage (more than 12 months prior to diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>51</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/24/45/sensitivity-data-5">
    <bmdb:SensSpecDetail>For late stage (within 12 months of diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>17</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-0">
    <bmdb:SensSpecDetail>Cases chosen with diagnosis of ovarian cancer (on average) 9 months prior. Controls were matched to cases by age and timing of specimen collection including general population controls (50%), false positive CA125 (25%), and family history of breast cancer (25%). All cases (n=60).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>12</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-1">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;lt;= 6 months after draw (n=25).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>21</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-2">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;gt; 6 months after draw (n=35).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>6</bmdb:Sensitivity>

    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-3">
    <bmdb:SensSpecDetail>For all cases, using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>12</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-4">

    <bmdb:SensSpecDetail>For early stage (more than 12 months prior to diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>14</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>

  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/46/sensitivity-data-5">
    <bmdb:SensSpecDetail>For late stage (within 12 months of diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>9</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-0">
    <bmdb:SensSpecDetail>Cases chosen with diagnosis of ovarian cancer (on average) 9 months prior. Controls were matched to cases by age and timing of specimen collection including general population controls (50%), false positive CA125 (25%), and family history of breast cancer (25%). All cases (n=60).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>22</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-1">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;lt;= 6 months after draw (n=25).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>46</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-2">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;gt; 6 months after draw (n=35).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>6</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-3">
    <bmdb:SensSpecDetail>For all cases, using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>24</bmdb:Sensitivity>

    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-4">
    <bmdb:SensSpecDetail>For early stage (more than 12 months prior to diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>31</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/26/47/sensitivity-data-5">

    <bmdb:SensSpecDetail>For late stage (within 12 months of diagnosis), using all controls. Results from preliminary analysis, 50% of 114 sample set. Daniel Cramer laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>14</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>

  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/34/54/sensitivity-data-0">
    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis.  Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>51</bmdb:Sensitivity>
    <bmdb:Specificity>82</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/35/55/sensitivity-data-0">
    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis.  Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>51</bmdb:Sensitivity>
    <bmdb:Specificity>82</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56/sensitivity-data-0">
    <bmdb:SensSpecDetail>Evaluation of AFP in early stage hepatocellular carcinoma. Early stage determined by tumor size via imaging. 419 cases total in the study; 208 early stage cases used in this analysis. Controls are individuals with chronic cirrohsis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>66</bmdb:Sensitivity>
    <bmdb:Specificity>82</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56/sensitivity-data-1">
    <bmdb:SensSpecDetail>Evaluation of AFP with DCP (biomarker combination) in early stage hepatocellular carcinoma. Early stage determined by tumor size via imaging. 419 cases total in the study; 208 early stage cases used in this analysis. Controls are individuals with chronic cirrohsis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>70</bmdb:Sensitivity>
    <bmdb:Specificity>80</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56/sensitivity-data-2">
    <bmdb:SensSpecDetail>Evaluation of AFP with DCP (biomarker combination) in cases with viral hepatitis (subset of cases inclusive of early and more advanced stage). Controls are individuals with chronic cirrohsis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>78</bmdb:Sensitivity>

    <bmdb:Specificity>84</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59/sensitivity-data-0">
    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>44</bmdb:Sensitivity>
    <bmdb:Specificity>51</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59/sensitivity-data-1">

    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>82</bmdb:Sensitivity>
    <bmdb:Specificity>26</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>

  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/39/60/sensitivity-data-0">
    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>51</bmdb:Sensitivity>
    <bmdb:Specificity>82</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/41/62/sensitivity-data-0">
    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>39</bmdb:Sensitivity>
    <bmdb:Specificity>51</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/41/62/sensitivity-data-1">
    <bmdb:SensSpecDetail>Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>82</bmdb:Sensitivity>
    <bmdb:Specificity>25</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/45/66/sensitivity-data-0">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For CDH13, AUC (95% confidence interval) was 0.515 (0.409, 0.622). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/46/67/sensitivity-data-0">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For NELL1, AUC (95% confidence interval) was 0.516 (0.420, 0.611). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>

    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/47/68/sensitivity-data-0">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For TAC1, AUC (95% confidence interval) was 0.571 (0.470, 0.673). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/49/69/sensitivity-data-0">

    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For RUNX3, AUC (95% confidence interval) was 0.671 (0.586, 0.756). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/50/70/sensitivity-data-0">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For HPP1, AUC (95% confidence interval) was 0.647 (0.556, 0.739). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/48/71/sensitivity-data-0">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For p16, AUC (95% confidence interval) was 0.628 (0.534, 0.722). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/51/72/sensitivity-data-0">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For SST, AUC (95% confidence interval) was 0.506 (0.401, 0.611). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>

    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/52/73/sensitivity-data-0">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For AKAP12, AUC (95% confidence interval) was 0.561 (0.451, 0.672). Summary of ROC statistics in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-0">

    <bmdb:SensSpecDetail>Panel alone, combined (2-yr and 4-yr progression models). 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>44</bmdb:Sensitivity>
    <bmdb:Specificity>90</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-1">
    <bmdb:SensSpecDetail>Panel-plus-age, combined (2-yr and 4-yr progression models). 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>46</bmdb:Sensitivity>
    <bmdb:Specificity>90</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-2">
    <bmdb:SensSpecDetail>Panel alone, combined (2-yr and 4-yr progression models). 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>63</bmdb:Sensitivity>
    <bmdb:Specificity>80</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-3">
    <bmdb:SensSpecDetail>Panel-plus-age, combined (2-yr and 4-yr progression models). 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>76</bmdb:Sensitivity>

    <bmdb:Specificity>80</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-4">
    <bmdb:SensSpecDetail>Panel alone, model of progression within 2 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>61</bmdb:Sensitivity>
    <bmdb:Specificity>90</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-5">

    <bmdb:SensSpecDetail>Panel alone, model of progression within 2 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>72</bmdb:Sensitivity>
    <bmdb:Specificity>80</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-6">
    <bmdb:SensSpecDetail>Panel-plus age, model of progression within 2 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>54</bmdb:Sensitivity>
    <bmdb:Specificity>90</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-7">
    <bmdb:SensSpecDetail>Panel-plus age, model of progression within 2 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>79</bmdb:Sensitivity>
    <bmdb:Specificity>80</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-8">
    <bmdb:SensSpecDetail>Panel alone, model of progression within 4 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>47</bmdb:Sensitivity>

    <bmdb:Specificity>90</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-9">
    <bmdb:SensSpecDetail>Panel alone, model of progression within 4 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>61</bmdb:Sensitivity>
    <bmdb:Specificity>80</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-10">

    <bmdb:SensSpecDetail>Panel-plus age, model of progression within 4 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>45</bmdb:Sensitivity>
    <bmdb:Specificity>90</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-11">
    <bmdb:SensSpecDetail>Panel-plus age, model of progression within 4 years. 195 biopsies of Barrett&amp;apos;s Esophagus (145 nonprogressors and 50 progressors).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>72</bmdb:Sensitivity>
    <bmdb:Specificity>80</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-12">
    <bmdb:SensSpecDetail>Definition of Barrett&amp;apos;s esophagus progressor patients and specimens: Barrett&amp;apos;s esophagus progressor patients are Barrett&amp;apos;s esophagus subjects with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. Progressor specimens (any Barrett&amp;apos;s esophagus tissues obtained prior to the progression endpoint) were divided into three subgroups - those obtained at 0-2 years, 2-4 years or more than 4 years prior to the progression endpoint. Non-progressor specimens were defined as Barrett&amp;apos;s esophagus and low-grade dysplasia tissues obtained at 0-2 years, 2-4 years, or more than 4 years before the non-progression follow-up date.
Progressors were considered both as a single combined group, and in two tiers: progression within 2 years (tier 1) or 4 years (tier 2). </bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>

    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-13">
    <bmdb:SensSpecDetail>Clinicopathic features of biopsies are summarized in the Related Resources section, in file &amp;quot;NP-P suppl table1.ppt&amp;quot;. [1]</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-14">

    <bmdb:SensSpecDetail>Normalized methylation values of HPP1, p16 and RUNX3 were significantly higher in progressors versus nonprogressors by Wilcoxon test. The remaining five markers did not differ significantly in progressors versus nonprogressors. Summarized in the Related Resources section, in file &amp;quot;NP-P suppl table 3.ppt&amp;quot;. [2]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-15">
    <bmdb:SensSpecDetail>Logistic regression analyses of the eight-marker panel: summarized in Related Resources section, file &amp;quot;Jin_Table1_LogisticRegression.doc&amp;quot;.  [3]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-16">
    <bmdb:SensSpecDetail>Receiver-operator characteristic (ROC) curves for the uncorrected 8-marker and 8-marker-plus-age panels, overfitting-corrected ROC curves for the 8-marker and 8-marker-plus-age panels, and ROC curves for age alone in the 2-, 4-year, and combined prediction models. A, Uncorrected ROC curve (AUC=0.843) and overfitting-corrected ROC curve (AUC=0.745) for 8-marker panel in 2-year prediction model; shrinkage due to overfitting correction minimal, at 0.098. B, Uncorrected ROC curve (AUC=0.829) and overfitting-corrected ROC curve (AUC=0.720) for 8-marker panel in 4-year prediction model; shrinkage minimal, at 0.109. C, Uncorrected ROC curve (AUC=0.840) and overfitting-corrected ROC curve (AUC=0.732) for 8-marker panel in combined prediction model; shrinkage minimal, at 0.108. D, Uncorrected ROC curve for 8-marker-plus-age panel (AUC=0.858), overfitting-corrected ROC curve (AUC=0.756), and ROC curve for age alone (0.604) in 2-year prediction model; increment over age alone substantial, at 0.152. E, Uncorrected ROC curve for 8-marker-plus-age panel (AUC=0.850), overfitting-corrected ROC curve (AUC=0.744), and ROC curve for age alone (0.630) in 4-year prediction model; increment over age alone substantial, at 0.114. F, Uncorrected ROC curve for 8-marker-plus-age panel (AUC=0.855), overfitting-corrected ROC curve (AUC=0.753), and ROC curve for age alone (0.635) in combined prediction model; increment over age alone substantial, at 0.118.  Graphs in Related Resources section, file &amp;quot;NP-P Supplementary fig 1.ppt&amp;quot; .  [4]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-17">
    <bmdb:SensSpecDetail>Incremental AUC values contributed by an eight-marker-plus-age biomarker panel to that of age alone, summarized in Related Resources section, file &amp;quot;Jin_Table2_IncrementalValues.doc&amp;quot;. [5]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>

    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-18">
    <bmdb:SensSpecDetail>Maintaining high specificity to minimize false-positive results, the model still predicted a number of new early diagnoses (diagnoses that would have not occurred earlier without the panel). Summarized in Related Resources section, file &amp;quot;Jin_Table3_SpecSens.doc&amp;quot;. [6]</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-19">

    <bmdb:SensSpecDetail>Predictiveness curves (risk plots) were used to assess the clinical utility of the combined classification rules in stratifying patients according to risk levels in the target population.  Summarized in Related Resources section, file &amp;quot;Jin_Table4_PredictCurve.doc&amp;quot;. [7]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-20">
    <bmdb:SensSpecDetail>Risk stratification of BE patients by predictiveness curves of 8-marker panel, age alone, and 8-marker-plus-age panel in combined, 2-year and 4-year prediction models. A, Predictiveness curve of 8-marker panel in combined model. After rigorous overfitting correction, at risk = 0.1 and = 0.5, 45% and 4% of subjects had estimated risks below 0.1 (LR group) and above 0.5 (HR group), respectively; while remaining 51% had estimated risks between 0.1 and 0.5 (IR group). B, Predictiveness curves of age alone and of 8-marker-plus-age panel in combined model. After rigorous overfitting correction, BE patients were stratified into LR (15%) and IR (85%) groups by age alone. BE patients were stratified into LR (51%), IR (44%) and HR (5%) groups by 8-marker-plus-age panel. C, Predictiveness curve of 8-marker panel in 2-year model. After rigorous overfitting correction, BE patients were stratified into LR (45%), IR (51%) and HR (4%) groups. D, Predictiveness curves of age alone and of 8-marker-plus-age panel in 2-year model. After rigorous overfitting correction, BE patients were stratified into LR (11%) and IR (89%) groups by age alone. BE patients were stratified into LR (52%), IR (44%) and HR (4%) groups by the 8-marker-plus-age panel. E, Predictiveness curve of the 8-marker panel alone in the 4-year model. After rigorous overfitting correction, BE patients were stratified into LR (44%), IR (51%) and HR (5%) groups. F, Predictiveness curves of age alone and of the 8-marker-plus-age panel in the 4-year model. After rigorous overfitting correction, BE patients were stratified into LR (15%) and IR (85%) groups by age alone. BE patients were stratified into LR (51%), IR (44%) and HR (5%) groups by 8-marker-plus-age panel. LR: low-risk; IR, intermediate-risk; HR: high-risk; OC: overfitting correction.  Graphs in Related Resources section, file &amp;quot;NP-P Supplementary fig 2.ppt&amp;quot;. [8]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/53/74/sensitivity-data-21">
    <bmdb:SensSpecDetail>Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50.  Summarized in Related Resources section, file &amp;quot;NP-P suppl table4.ppt&amp;quot;. [8]</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-0">
    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). For the average of unnormalized TSP, AUC was 0.52 (0.42, 0.62).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>90</bmdb:Sensitivity>

    <bmdb:Specificity>10</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-1">
    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). For the average of normalized TSP, AUC was 0.5 (0.4, 0.61).</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>90</bmdb:Sensitivity>
    <bmdb:Specificity>5</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-2">

    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing cases with Gleason grade &amp;gt;=7 (n=30) to the pool of controls and cases with Gleason grade &amp;lt;7 (n=93), for the average of unnormalized TSP, AUC was 0.53 (0.41, 0.66).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>90</bmdb:Sensitivity>
    <bmdb:Specificity>6</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>

    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75/sensitivity-data-3">
    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing cases with Gleason grade &amp;gt;=7 (n=30) to the pool of controls and cases with Gleason grade &amp;lt;7 (n=93), for the average of normalized TSP, AUC was 0.54 (0.42, 0.66).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>90</bmdb:Sensitivity>
    <bmdb:Specificity>13</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77/sensitivity-data-0">
    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing cases with Gleason grade &amp;gt;=7 (n=30) to the pool of controls and cases with Gleason grade &amp;lt;7 (n=93), the AUC was 0.63 (0.52, 0.75). No specific cutoff was preselected for this analysis.</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/56/77/sensitivity-data-1">

    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.59 (0.48, 0.69). No specific cutoff was preselected for this analysis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78/sensitivity-data-0">
    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing cases with Gleason grade &amp;gt;=7 (n=30) to the pool of controls and cases with Gleason grade &amp;lt;7 (n=93), the AUC was 0.55 (0.45, 0.64). No specific cutoff was preselected for this analysis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>
    <bmdb:Specificity>0</bmdb:Specificity>

    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/57/78/sensitivity-data-1">
    <bmdb:SensSpecDetail>Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;lt;7) and 30 had high Gleason grade (&amp;gt;=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.52 (0.44, 0.60). No specific cutoff was preselected for this analysis.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>

    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108/sensitivity-data-0">
    <bmdb:SensSpecDetail>Cases chosen with diagnosis of ovarian cancer (on average) 9 months prior. Controls were matched to cases by age and timing of specimen collection including general population controls (50%), false positive CA125 (25%), and family history of breast cancer (25%). All cases (n=60).</bmdb:SensSpecDetail>

    <bmdb:Sensitivity>47</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108/sensitivity-data-1">

    <bmdb:SensSpecDetail>Cases diagnosed &amp;lt;= 6 months after draw (n=25).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>78</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>

  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/89/108/sensitivity-data-2">
    <bmdb:SensSpecDetail>Cases diagnosed &amp;gt; 6 months after draw (n=35).</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>26</bmdb:Sensitivity>
    <bmdb:Specificity>95</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>

    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
  <bmdb:SensitivityData rdf:about="http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/90/109/sensitivity-data-0">
    <bmdb:SensSpecDetail>Definition of Barrett&amp;apos;s esophagus progressor patients and specimens: Barrett&amp;apos;s esophagus progressor patients are Barrett&amp;apos;s esophagus subjects with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. Progressor specimens (any Barrett&amp;apos;s esophagus tissues obtained prior to the progression endpoint) were divided into three subgroups - those obtained at 0-2 years, 2-4 years or more than 4 years prior to the progression endpoint. Non-progressor specimens were defined as Barrett&amp;apos;s esophagus and low-grade dysplasia tissues obtained at 0-2 years, 2-4 years, or more than 4 years before the non-progression follow-up date.</bmdb:SensSpecDetail>
    <bmdb:Sensitivity>0</bmdb:Sensitivity>

    <bmdb:Specificity>0</bmdb:Specificity>
    <bmdb:Prevalence>0</bmdb:Prevalence>
    <bmdb:NPV></bmdb:NPV>
    <bmdb:PPV></bmdb:PPV>
  </bmdb:SensitivityData>
</rdf:RDF>
